Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients

N Wu, J Dai, M Guo, J Li, X Zhou, F Li… - Emerging microbes & …, 2021 - Taylor & Francis
N Wu, J Dai, M Guo, J Li, X Zhou, F Li, Y Gao, H Qu, H Lu, J Jin, T Li, L Shi, Q Wu, R Tan…
Emerging microbes & infections, 2021Taylor & Francis
Phage therapy is recognized as a promising alternative to antibiotics in treating pulmonary
bacterial infections, however, its use has not been reported for treating secondary bacterial
infections during virus pandemics such as coronavirus disease 2019 (COVID-19). We
enrolled 4 patients hospitalized with critical COVID-19 and pulmonary carbapenem-resistant
Acinetobacter baumannii (CRAB) infections to compassionate phage therapy (at 2
successive doses of 109 plaque-forming unit phages). All patients in our COVID-19-specific …
Abstract
Phage therapy is recognized as a promising alternative to antibiotics in treating pulmonary bacterial infections, however, its use has not been reported for treating secondary bacterial infections during virus pandemics such as coronavirus disease 2019 (COVID-19). We enrolled 4 patients hospitalized with critical COVID-19 and pulmonary carbapenem-resistant Acinetobacter baumannii (CRAB) infections to compassionate phage therapy (at 2 successive doses of 109 plaque-forming unit phages). All patients in our COVID-19-specific intensive care unit (ICU) with CRAB positive in bronchoalveolar lavage fluid or sputum samples were eligible for study inclusion if antibiotic treatment failed to eradicate their CRAB infections. While phage susceptibility testing revealed an identical profile of CRAB strains from these patients, treatment with a pre-optimized 2-phage cocktail was associated with reduced CRAB burdens. Our results suggest the potential of phages on rapid responses to secondary CRAB outbreak in COVID-19 patients.
Taylor & Francis Online
以上显示的是最相近的搜索结果。 查看全部搜索结果

Google学术搜索按钮

example.edu/paper.pdf
查找
获取 PDF 文件
引用
References